Zachary A. Cooper

Research interests

Publications

• Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01406-6

• The human tumor microbiome is composed of tumor type–specific intracellular bacteria

  Science · 2020 · https://doi.org/10.1126/science.aay9189

• Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0724-8

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.10.038

• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30015-9

• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  Science · 2017 · https://doi.org/10.1126/science.aan4236

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

  Science Translational Medicine · 2017 · https://doi.org/10.1126/scitranslmed.aah3560

• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

  Science · 2017 · https://doi.org/10.1126/science.aah5043

• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

  Cancer Cell · 2016 · https://doi.org/10.1016/j.ccell.2016.02.003

• RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

  Nature · 2016 · https://doi.org/10.1038/nature17392

• Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

  Cancer Discovery · 2016 · 10.1158/2159-8290.cd-15-1545

• The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3218

• Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

  Cancer Discovery · 2015 · https://doi.org/10.1158/2159-8290.cd-15-0283

• Systematic identification of signaling pathways with potential to confer anticancer drug resistance

  Science Signaling · 2014 · https://doi.org/10.1126/scisignal.aaa1877

• Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

  Cancer Research · 2014 · https://doi.org/10.1158/0008-5472.can-14-1392

• A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

  Cancer Discovery · 2014 · https://doi.org/10.1158/2159-8290.cd-13-0424

• Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

  Cancer Immunology Research · 2014 · https://doi.org/10.1158/2326-6066.cir-13-0215

• The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

  Cancer Discovery · 2014 · https://doi.org/10.1158/2159-8290.cd-13-1007

• Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

  Cancer Discovery · 2013 · https://doi.org/10.1158/2159-8290.cd-13-0005

• MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

  Cancer Discovery · 2013 · https://doi.org/10.1158/2159-8290.cd-13-0631

• BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

  Clinical Cancer Research · 2013 · https://doi.org/10.1158/1078-0432.ccr-12-1630

• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-12-1626

• Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

  Nature · 2012 · https://doi.org/10.1038/nature11183

• Elucidating Distinct Roles for NF1 in Melanomagenesis

  Cancer Discovery · 2012 · https://doi.org/10.1158/2159-8290.cd-12-0313

• Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-12-1632

Current projects

No projects listed.